ENZCEnzolytics Inc.

About Enzolytics Inc. (ENZC)

Enzolytics Inc. (ENZC) is a Biotechnology company headquartered in ALLEN, TX, United States whose shares trade over-the-counter on the Pink tier.

Business Description Enzolytics, Inc. (the "Company" or "ENZC") is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. The Company is committed to creating drugs for the better health of mankind. ENZC's flagship compound ITV-1 is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from major neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use today. IPF has not shown to be subject to viral resistance and is cost effective.

Products and services

The Company’s products consist of two distinct drug development proprietary technologies: Immunotherapy and fully human monoclonal antibodies. Enzolytics has proprietary technology for creating human cell lines that produce fully human monoclonal antibodies against numerous infectious diseases, including HIV-1, Hepatitis (A, B, C), rabies, influenza A and B, tetanus and diphtheria. The Company’s technology for producing fully human monoclonal antibodies is now being employed to produce anti-SARS-CoV-2 (Coronavirus) monoclonal antibodies for treating COVID-19. The Company plans to employ its technology to subsequently produce fully human monoclonal antibodies for treating HIV-2, anthrax, smallpox, H1N1 influenza, herpes zoster, varicella zoster, Rh (+) auto-immune disease and the Ebolavirus. The Company is in the final development of the recombinant of the parent anti-HIV monoclonal antibody (identified as “Clone 3”) which has been shown in in vitro tests conducted in 5 international laboratories to fully neutralized over 95% of all strains and viral subtypes of HIV-1 against which it was tested. The basis for its broad-spectrum efficacy is the fact that Clone 3 antibody targets an immutable epitope on the HIV virus. The targeted epitope has remained present in 98% (either directly or by way of conserved substitutions) of the 87,336 HIV isolates now known which have been analyzed by the Company using Artificial Intelligence (AI).

ENZC key facts

Ticker symbol

ENZC

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

ALLEN, TX, United States

Country of incorporation

US

Year of incorporation

2007

Employees

6

Estimated market cap

$2.90M (as of Apr 9, 2025)

Shares outstanding

4,831,062,901

Reporting standard

Alternative Reporting Standard

Audit status

Unaudited

Fiscal year end

12/31

Latest filing

Quarterly Report (Jun 30, 2024)

Enzolytics Inc. leadership

• Jeremy Phillip Frommer — CEO
• Diana Zhabilov — CFO
• Harry H. Zhabilov , Jr. — CSO, Company Secretary

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with E